Related Experiment Video

Updated: May 5, 2026

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD
09:47

Standardized Measurement of Nasal Membrane Transepithelial Potential Difference NPD

Published on: September 13, 2018

16.3K

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del

Nicole Reyne1,2,3, Patricia Cmielewski1,2,3, Alexandra McCarron1,2,3

  • 1Robinson Research Institute, University of Adelaide, Adelaide, SA, Australia.

Frontiers in Pharmacology
|June 12, 2024
PubMed

Keywords:
CFTR modulatorX-ray velocimetrycystic fibrosislung functionnasal potential differencerat model

More Related Videos

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice08:55

Nasal Potential Difference to Quantify Trans-epithelial Ion Transport in Mice

Published on: July 4, 2018

7.7K
Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine08:35

Primary Human Nasal Epithelial Cells: Biobanking in the Context of Precision Medicine

Published on: April 22, 2022

2.8K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97